The U.S. Food and Drug Administration has approved Semintra (telmisartan oral solution) to control systemic hypertension in cats. Systemic hypertension occurs most commonly in cats with chronic kidney disease (CKD) but can also develop in cats with no identifiable underlying cause, or along with other chronic disease conditions. The active ingredient, telmisartan, is an angiotensin II receptor blocker that reduces blood pressure by relaxing blood vessels. Prescribing veterinarians should monitor blood pressure regularly and adjust the dose as needed, the FDA states. Cats with CKD should be monitored early in treatment for potential changes in kidney values. When starting treatment, all cats should be monitored for the development of anemia and changes in appetite or for side effects such as vomiting, diarrhea or weight loss, according to the FDA.